-+ 0.00%
-+ 0.00%
-+ 0.00%

XORTX closes acquisition of Vectus kidney anti-fibrotic asset for US$3 million

PUBT·04/13/2026 21:00:30
Listen to the news
XORTX closes acquisition of Vectus kidney anti-fibrotic asset for US$3 million
  • XORTX closed acquisition of Vectus Biosystems’ kidney anti-fibrotic program centered on pre-IND compound VB4-P5.
  • Deal value set at USD 3 million, paid with 154,544 common shares plus 692,150 pre-funded warrants.
  • Acquired package includes intellectual property, regulatory documentation, manufacturing data, and a patent family covering VB4-P5 use in kidney fibrosis.
  • XORTX positioned VB4-P5 as a potential treatment for mid-to-late stage chronic kidney disease, targeting fibrosis and disease progression.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604131700PRIMZONEFULLFEED9688877) on April 13, 2026, and is solely responsible for the information contained therein.